APHB Key Statistics, Chart & Performance
The current stock price of APHB is 0.3179 null. In the past month the price increased by 9.62%. In the past year, price decreased by -71.1%.
APHB Latest News, Press Relases and Analysis
About APHB
Company Profile
AmpliPhi Biosciences Corporation, formerly known as Targeted Genetics Corporation, is a biotechnology company which develops anti-bacterial solutions for the treatment of gram negative bacterial infections that are often resistant to existing antibiotic treatments. AmpliPhi Biosciences Corporation is based in Seattle, Washington.
Company Info
AMPLIPHI BIOSCIENCES CORP
3579 VALLEY CENTRE DRIVE SUITE 100
SAN DIEGO CA 92130
CEO: Paul C. Grint
Phone: 804-827-2524
AMPLIPHI BIOSCIENCES CORP / APHB FAQ
What does AMPLIPHI BIOSCIENCES CORP do?
AmpliPhi Biosciences Corporation, formerly known as Targeted Genetics Corporation, is a biotechnology company which develops anti-bacterial solutions for the treatment of gram negative bacterial infections that are often resistant to existing antibiotic treatments. AmpliPhi Biosciences Corporation is based in Seattle, Washington.
Can you provide the latest stock price for AMPLIPHI BIOSCIENCES CORP?
The current stock price of APHB is 0.3179 null. The price decreased by -20.33% in the last trading session.
Does AMPLIPHI BIOSCIENCES CORP pay dividends?
APHB does not pay a dividend.
How is the ChartMill rating for AMPLIPHI BIOSCIENCES CORP?
APHB has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
APHB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to APHB. When comparing the yearly performance of all stocks, APHB is a bad performer in the overall market: 85.39% of all stocks are doing better.
APHB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APHB. Both the profitability and financial health of APHB have multiple concerns.
APHB Financial Highlights
Over the last trailing twelve months APHB reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 60.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.95% | ||
| ROE | -253.84% | ||
| Debt/Equity | 0 |